In this work, we demonstrated that CD4+Foxp3+LAP+ Treg population was modestly increased in the peripheral blood of CRC patients and presented a distinct subset of activated Tregs that potently suppressed effector cells through a TGF-β–related mechanism. This evidence concerns the gene FOXP3 and colorectal carcinoma.